Intent-to-treat median PFS was 10.2 months with nivolumab/ipilimumab versus 6.3 months with added SBRT, with 12-month PFS 47.8% versus 34.9% (HR 1.20; P=.56). Per-protocol analysis after four ...

At the 2026 Miami Breast Cancer Conference, Kevin Kalinsky, MD, MS, participated in a molecular tumor board session that brought together a multidisciplinary panel including medic ...

A 1 kg/m2 increase in maternal BMI increased the odds of offspring MASLD by 10%, and an increase in paternal BMI by the same amount increased the risk by 9%. Offspring with two parents who had ...

This March, join the Alliance for Clinical Trials in Oncology (Alliance) and the Alliance Foundation Trials (AFT) in spotlighting colorectal cancer, the second leading cause of cancer-related death in ...

Currently, no consensus exists regarding the definition of oligometastatic pancreatic ductal adenocarcinoma, its necessary diagnostic measures, and potential treatment approaches. To address these ...

A phase 2 trial showed that combining targeted radiotherapy with PD-1 blockade and a bevacizumab biosimilar can elicit responses in advanced liver cancer.

Aga Khan University Hospital, Nairobi (AKUH), has unveiled an AI-enabled radiotherapy system valued at KES 800 million, designed to deliver highly ...

New research from a University of Cincinnati Cancer Center study found external beam radiation therapy (EBRT) is safe to ...

New molecular insights into the link between hepatocellular carcinoma and intratumoral fibrosis could lead to better ...

In the absence of trials, a post hoc analysis compared stereotactic body radiotherapy (SBRT) and high-dose-rate brachytherapy (HDR-BT) in intermediate-risk prostate cancer.

A Rutgers-led study found that eating less protein may help slow liver cancer in people with impaired liver function. When ...